BMS/Pfizer's Eliquis better than Sanofi's Lovenox for hip but not knee, IQWiG says
This article was originally published in Scrip
Executive Summary
Pfizer/Bristol-Myers Squibb's anticoagulant Eliquis (apixaban) is slightly better than the low-molecular weight heparin enoxaparin (Sanofi's Lovenox)at preventing symptomatic venous thromboembolism after hip replacement, but is less beneficial than the comparator following knee replacement surgery, says IQWiG, Germany's Institute for Quality and Efficiency.